Abstract Number: 1126 • 2015 ACR/ARHP Annual Meeting
Pyrrolopyrimidine Derivatives That Inhibit BAFF Binding to Its Receptor, BR3, Decrease IgG Production By B Cells in Vitro and in Vivo Model of Autoimmune Diseases
Background/Purpose: We have found that the expression level of BAFF receptor (BR3) is abnormally enhanced in peripheral monocytes of patients with pSS, and BAFF robustly…Abstract Number: 2696 • 2014 ACR/ARHP Annual Meeting
Relationship Between Soluble sCD23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab
Background/Purpose CD23 is the low-affinity receptor for IgE (FceRII). The soluble form, sCD23 is released into the circulation and in vitro this is consistent with…Abstract Number: 2695 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab
Background/Purpose: Systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA) are autoimmune diseases which develop secondary to immune self-tolerance failure. Both diseases are characterised in…Abstract Number: 1974 • 2014 ACR/ARHP Annual Meeting
Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon–gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts
Background/Purpose B cell activating factor of the tumor necrosis factor family (BAFF) is a cytokine important for the stimulation and survival of autoreactive B cells…Abstract Number: 1640 • 2014 ACR/ARHP Annual Meeting
Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus
Background/Purpose . B cell activating factor of tumor necrosis factor family (BAFF) is a positive regulator of B cell function and expressed in dendritic cells,…Abstract Number: 857 • 2014 ACR/ARHP Annual Meeting
Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Background/Purpose: BAFF, a potent B cell survival factor, is an established therapeutic target in SLE, with the anti-BAFF antibody, belimumab, being FDA-approved for the treatment…Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…Abstract Number: 1741 • 2013 ACR/ARHP Annual Meeting
Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Background/Purpose: The interferon alpha (IFN) gene signature is frequent in SLE (~50% of patients) and important in pathogenesis. However, multiple studies have found that the…Abstract Number: 1742 • 2013 ACR/ARHP Annual Meeting
Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on IgG, IgM and infection risk in patients…Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting
B Cells Revisited In Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…Abstract Number: 722 • 2013 ACR/ARHP Annual Meeting
BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice
Background/Purpose: BAFF (B cell activating factor belonging to the TNF family) promotes B cells maturation in germinal center. The generation of germinal center depends on…Abstract Number: 511 • 2013 ACR/ARHP Annual Meeting
Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren’ssyndrome: Results Of The Beliss Study
Background/Purpose: To address the change in labial salivary gland (LSG) inflammation after Belimumab (biological treatment inhibiting soluble BAFF/BLyS) therapy in pSS patients and identify predictor…Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
ACR Meeting Abstracts